Table 2.
Characteristics of the developing cohort patients and the validation cohort patients with brain metastases from non-small cell lung cancer
| Characteristics | Developing cohort (n = 223) | Validation cohort (n = 112) | |
|---|---|---|---|
| N (%) | p value | N (%) | |
| Gender | 0.013 | ||
| Male | 144 (64.6%) | 73 (65.2%) | |
| Female | 79 (35.4%) | 39 (34.8%) | |
| Age of BM diagnosis(years) | 0.311 | ||
| < 60 | 134 (60.1%) | 61 (54.5%) | |
| ≥ 60 | 89 (39.9%) | 51 (45.5%) | |
| KPS (%) | <0.001 | ||
| ≥ 80 | 99 (44.4%) | 45 (40.6%) | |
| < 80 | 124 (55.6%) | 67 (59.4%) | |
| Interval from NSCLC diagnosis to BM diagnosis | 0.044 | ||
| Synchronous | 159 (71.3%) | 86 (76.8%) | |
| Metachronous | 64 (28.7%) | 26 (23.2%) | |
| Time from neural symptom onset to BM diagnosis(months) | 0.759 | ||
| ≤ 1 | 159 (71.3%) | 81 (72.3%) | |
| 1–3 | 45 (20.2%) | 25 (22.3%) | |
| > 3 | 19 (8.5%) | 6 (5.4%) | |
| ECM when BM diagnosis | 0.009 | ||
| Yes | 85 (38.1%) | 35 (31.3%) | |
| No | 138 (61.9%) | 77 (68.8%) | |
| Number of BM | 0.925 | ||
| 1 | 148 (66.3%) | 70 (62.5%) | |
| 2 | 11 (5.0%) | 14 (12.5%) | |
| 3 | 64 (28.7%) | 28 (25.0%) | |
| Tumor size(cm) | 0.348 | ||
| ≤ 2 | 62 (27.8%) | 26 (23.2%) | |
| > 2 | 124 (55.6%) | 67 (59.8%) | |
| Unknown | 37 (16.6%) | 19 (17.0%) | |
| Histology | 0.006 | ||
| Adenocarcinoma | 116 (52.2%) | 75 (67.0%) | |
| Squamous cell lung cancer | 25 (11.2) | 20 (17.9%) | |
| Poorly differentiated carcinoma or histology can’t be distinguished | 82 (36.8%) | 17 (15.1%) | |
BM brain metastases, KPS Karnofsky performance status, ECM extracranial metastases